MajorSerotonin antagonist and reuptake inhibitor (SARI) antidepressant×SNRI (serotonin-norepinephrine reuptake inhibitor)
Updated · Methodology
Mechanism
Trazodone prolongs the QT interval, and postmarketing reports include torsade de pointes (trazodone label, US Food and Drug Administration, FDA; trazodone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The venlafaxine SmPC warns that the risk of QT prolongation and ventricular arrhythmia rises with other drugs that prolong the QT interval (venlafaxine SmPC, AEMPS). In a study at 450 mg a day, venlafaxine itself did not prolong the QT interval to a clinically relevant degree. Postmarketing cases of QT prolongation and torsade de pointes have been reported, especially in overdose or with other risk factors (venlafaxine SmPC, AEMPS). Both drugs increase serotonin activity. Serotonin syndrome has been described when trazodone was combined with serotonin and noradrenaline reuptake inhibitors (SNRIs), the group venlafaxine belongs to (trazodone SmPC, AEMPS). Venlafaxine weakly inhibits the enzyme CYP2D6 and does not inhibit CYP3A4, which forms the active metabolite of trazodone in the liver. The documents report no pharmacokinetic study of this pair (venlafaxine and trazodone SmPCs, AEMPS).
Symptoms
QT interval prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). Torsade de pointes, a ventricular tachycardia, causes palpitations, dizziness and fainting. Serotonin syndrome presents with agitation, hallucinations, a fast pulse, unstable blood pressure, fever, overactive reflexes, poor coordination, nausea, vomiting and diarrhoea. In its severe form it resembles neuroleptic malignant syndrome, with muscle rigidity and altered mental state (venlafaxine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Trazodone causes somnolence and a drop in blood pressure on standing, sometimes with fainting, more often in older people (trazodone SmPC, AEMPS).
Management
The venlafaxine summary of product characteristics (SmPC) says to avoid combining venlafaxine with other drugs that prolong the QT interval, and trazodone prolongs QT according to its own documents (venlafaxine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; trazodone label, US Food and Drug Administration, FDA, and trazodone SmPC, AEMPS). The Spanish trazodone SmPC advises caution when combining trazodone with QT-prolonging drugs (trazodone SmPC, AEMPS). The UK National Institute for Health and Care Excellence (NICE) allows adding an antidepressant from a different class, for example trazodone to a selective serotonin reuptake inhibitor, when depression has had no response or a limited response to an antidepressant. NICE also advises considering referral to a specialist mental health service or consulting a specialist, and explaining to the patient in advance that side effects may increase (NICE NG222). In people at high risk of serious arrhythmia or QT prolongation, weigh the benefit and risk before prescribing venlafaxine (venlafaxine SmPC, AEMPS). Avoid trazodone in people with a history of arrhythmias, symptomatic bradycardia, low potassium or magnesium, or congenital QT prolongation (trazodone FDA label). Somnolence and orthostatic hypotension from trazodone can add to the effects of other psychotropic drugs, especially in older people. Warn the patient or carer and watch these effects closely after the start and before and after each dose increase (trazodone SmPC, AEMPS). Use venlafaxine with caution together with other drugs acting on the central nervous system (venlafaxine SmPC, AEMPS). If the combination is clinically justified, observe the patient carefully, particularly at the start of treatment and after dose increases (venlafaxine SmPC, AEMPS). If serotonin syndrome appears, stop both drugs at once and start symptomatic treatment (venlafaxine FDA label; trazodone SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Effexor XR (venlafaxine) prescribing information (2023)– FDA label, Viatris Specialty LLC, DailyMed setid c848a5d8-ba94-4c84-80e3-0bf35fb8e32e, revised 08/2023, sections 5.4, 7 and 17
- AEMPS: Ficha técnica: Vandral Retard 75 mg (venlafaxina, nº registro 62401), sección 4.5 (2024)– AEMPS, CIMA, nº registro 62401, revisión 05/2024, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Trazodona (nº registro 78585), sección 4.5 (2026)– AEMPS, CIMA, nº registro 78585 (Trazodona Normon 100 mg), revisión 06/2026, secciones 4.4 y 4.5
- FDA: RALDESY (trazodone hydrochloride) prescribing information (2026)– FDA, DailyMed setid 34708cc1-b0b2-4fd0-b9f3-7f008b457fc9 (Validus), revisión 09/2026 (versión 6), secciones 5.2, 5.3, 5.9 y 7
- NICE: Depression in adults: treatment and management (NG222), further-line treatment (2022)– NICE guideline NG222, published 06/2022, recommendations 1.9.8–1.9.9 (adding trazodone to an SSRI as a further-line option)